Why the study?
Does candesartan-based antihypertensive treatment reduce major cardiovascular events, cognitive decline, and dementia in elderly patients with mildly to moderately elevated blood pressure?
Does candesartan-based antihypertensive treatment reduce major cardiovascular events, cognitive decline, and dementia in elderly patients with mildly to moderately elevated blood pressure?
In elderly patients with mildly to moderately elevated blood pressure, candesartan-based therapy did not significantly reduce major cardiovascular events compared to control therapy, but it did significantly reduce non-fatal stroke.
No takes yet. Share an insight, caveat, or question.
Candesartan-based therapy does not significantly reduce major cardiovascular events; confirms lack of benefit for the primary endpoint in elderly mild-moderate hypertension.
Lithell et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: